The Use of an Extracorporeal Membrane Oxygenation Anticoagulation Laboratory Protocol Is Associated With Decreased Blood Product Use, Decreased Hemorrhagic Complications, and Increased Circuit Life*
- 1 January 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pediatric Critical Care Medicine
- Vol. 16 (1), 66-74
- https://doi.org/10.1097/pcc.0000000000000278
Abstract
Objectives: To determine if a comprehensive extracorporeal membrane oxygenation anticoagulation monitoring protocol results in fewer hemorrhagic complications, reduced blood product usage, and increased circuit life. Design: In September 2011, we augmented our standard extracorporeal membrane oxygenation laboratory protocol to include anti-factor Xa assays, thromboelastography, and antithrombin measurements. We performed a retrospective chart review to determine outcomes for patients placed on extracorporeal membrane oxygenation prior to and after the initiation of our anticoagulation laboratory protocol. Setting: Tertiary care, academic children's hospital. Patients: All patients who were placed on extracorporeal membrane oxygenation at our institution from January 1, 2007, to September 30, 2013. Interventions: None. Measurements and Main Results: There were 261 extracorporeal membrane oxygenation runs before the initiation of the protocol and 105 extracorporeal membrane oxygenation runs after the initiation of the protocol. There were no major changes to our extracorporeal membrane oxygenation circuit or changes to our transfusion threshold during the study period. The indication for extracorporeal membrane oxygenation, age, and severity of illness of the patients were similar before and after protocol initiation. Median blood product usage for packed RBCs, fresh frozen plasma, platelets, and cryoprecipitate decreased significantly after protocol initiation. The occurrence of cannula site bleeding decreased from 22% to 120% (p = 0.04), and surgical site bleeding decreased from 38% to 25% (p = 0.02). Median extracorporeal membrane oxygenation circuit life increased from 3.6 to 4.3 days (p = 0.02). A trend toward increased patient survival was noted, but it did not reach statistical significance. Conclusions: We demonstrate an association between an extracorporeal membrane oxygenation anticoagulation laboratory protocol using anti-factor Xa assays, thromboelastography, and antithrombin measurements and a decrease in blood product transfusion, a decrease in hemorrhagic complications, and an increase in circuit life. To our knowledge, this is the first study to demonstrate clinical benefit associated with the use of these laboratory values for patients on extracorporeal membrane oxygenation.Keywords
This publication has 33 references indexed in Scilit:
- Transfusion-related acute lung injury: a clinical reviewThe Lancet, 2013
- Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort studyCritical Care, 2013
- Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenationPerfusion, 2012
- Antithrombin Replacement During Extracorporeal Membrane OxygenationArtificial Organs, 2011
- Increased Odds of Necrotizing Enterocolitis After Transfusion of Red Blood Cells in Premature InfantsPublished by American Academy of Pediatrics (AAP) ,2011
- Red blood cell transfusion in critically ill children: A narrative review*Pediatric Critical Care Medicine, 2011
- Evaluation of Heparin Assay for Coagulation Management in Newborns Undergoing ECMOAmerican Journal of Clinical Pathology, 2010
- Incidence and transfusion risk factors for transfusion‐associated circulatory overload among medical intensive care unit patientsTransfusion, 2010
- Association between length of storage of red blood cell units and outcome of critically ill children: a prospective observational studyCritical Care, 2010
- Assessing Heparin Dosing in Neonates on Venoarterial Extracorporeal Membrane OxygenationASAIO Journal, 2007